Skip to Content
Merck
All Photos(3)

Key Documents

SML0534

Sigma-Aldrich

Verteporfin

≥94% (HPLC), powder, YAP-TEA domain interaction inhibitor

Synonym(s):

(4R,4aS)-rel-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-24H,26H-Benzo[b]porphine-9,13-dipropanoic acid monomethyl ester, Visudyne, trans-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-Benzo[b]porphine-9,13-dipropanoic acid monomethyl ester

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C41H42N4O8
CAS Number:
Molecular Weight:
718.79
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

product name

Verteporfin, ≥94% (HPLC)

Quality Level

Assay

≥94% (HPLC)

form

powder

storage condition

desiccated
protect from light

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

−20°C

SMILES string

CC(C(/C=C1[C@@]2(C)C(/C(N/1)=C/3)=CC=C(C(OC)=O)[C@H]2C(OC)=O)=N/4)=C(CCC(OC)=O)C4=C\C5=C(CCC(O)=O)C(C)=C(/C=C6C(C=C)=C(C)C3=N/6)N5.CC(C(/C=C7[C@@]8(C)C(/C(N/7)=C/9)=CC=C(C(OC)=O)[C@H]8C(OC)=O)=N/%10)=C(CCC(O)=O)C%10=C\C%11=C(CCC(OC)=O)C(C)=C(/C=C%12C(C=C)

InChI

1S/2C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)24(11-14-36(46)47)32(44-30)18-33-25(12-15-37(48)51-6)21(3)28(43-33)16-31(23)42-29;1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h2*9-10,13,16-19,38,43,45H,1,11-12,14-15H2,2-8H3,(H,46,47)/b31-16-,32-18-,34-17-,35-19-;31-16-,33-18-,34-17-,35-19-/t2*38-,41+/m00/s1

InChI key

YHNBVDZVUQFVLS-SKJZPIBWSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Verteporfin has been used as a photosensitizer. It is also used as an inhibitor of YAP (Yes-associated protein)-TEA domain (TEAD) interaction.

Biochem/physiol Actions

Verteporfin has an ability to disrupt the interaction between YAP (Yes-associated protein)/TAZ (transcriptional coactivator with PDZ-binding motif) and TEA domain (TEAD) complex. It also reduces the viability of the ovarian cancer cells and almost eliminates cell migration. Therefore, verteporfin might be considered as a potent therapeutic for ovarian cancer.
Verteporfin is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as macular degeneration. Verteporfin accumulates in abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels. Verteporfin localizes predominantly in mitochondria.

Other Notes

Light sensitive

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yukari Mae et al.
Molecular and clinical oncology, 13(3), 10-10 (2020-08-06)
Photodynamic therapy (PDT) induces photochemical reactions, resulting in the destruction of tumor cells via singlet (S1) oxygen production. This cellular destruction occurs specifically in tumor cells, following selective accumulation of a photosensitizer and its excitation by a specific wavelength. Verteporfin
Wai Man Chan et al.
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 248(5), 613-626 (2010-02-18)
Verteporfin photodynamic therapy (PDT) is approved for the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD), as well as for subfoveal CNV due to pathologic myopia and ocular histoplasmosis syndrome. Verteporfin PDT addresses the
Anders Pryds et al.
Retina (Philadelphia, Pa.), 33(1), 128-135 (2012-12-28)
To assess the prognostic effect of subretinal deposits in eyes with central serous chorioretinopathy (CSC). The study included 21 eyes with foveal detachment and subretinal deposits at presentation that underwent photodynamic therapy (PDT). No symptoms or signs of CSC were
Overexpression of TAZ promotes cell proliferation, migration and epithelial-mesenchymal transition in ovarian cancer.
Chen G, et al.
Oncology Letters, 12(3), 1821-1825 (2016)
Yong-Kyu Kim et al.
American journal of ophthalmology, 160(1), 72-84 (2015-04-19)
To investigate long-term changes in subfoveal choroidal thickness (SCT) after photodynamic therapy (PDT) and their relationship with chronic central serous chorioretinopathy (CSC) recurrence. Retrospective, observational, comparative case series. Fifty-seven eyes with chronic CSC (52 patients, ≥2 years follow-up) treated with

Articles

DISCOVER Bioactive Small Molecules for Nitric Oxide & Cell Stress Research

DISCOVER Bioactive Small Molecules for Nitric Oxide & Cell Stress Research

DISCOVER Bioactive Small Molecules for Nitric Oxide & Cell Stress Research

DISCOVER Bioactive Small Molecules for Nitric Oxide & Cell Stress Research

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service